The Food and Drug Administration Friday approved the first generic naloxone nasal spray, an emergency treatment for opioid overdose intended for use in the community. Generic injectable naloxone products have been available for use in health care settings for years. The FDA has previously approved a brand-name naloxone nasal spray and an auto-injector for use by those without medical training. “In addition to this approval of the first generic naloxone nasal spray, moving forward we will prioritize our review of generic drug applications for naloxone,” said Douglas Throckmorton, M.D., deputy center director for regulatory programs at the FDA’s Center for Drug Evaluation and Research.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services Feb. 8 released a proposed rule intended to strengthen oversight of organizations that accredit health care…
Headline
The Department of Health and Human Services’ Office for Civil Rights Jan. 25 released guidance reminding hospitals, critical access hospitals and long-term…
Headline
The Centers for Medicare & Medicaid Services Dec. 4 released an interim final rule implementing new enforcement authorities the agency will use if states…
Headline
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…
Headline
The Food and Drug Administration Sept. 29 released a proposed rule that would phase out over four years its general enforcement discretion approach for most…
News
As proposed yesterday by its Advisory Committee on Immunization Practices, the Centers for Disease Control and Prevention recommends that starting this fall…